Grant Lawless developed and manages the MS programs in Healthcare Decision Analysis (HCDA) and Biopharmaceutical Marketing at USC. These novel master's degrees are part of an intensive, interdisciplinary program designed to train graduates from across the globe who hold undergraduate degrees in the sciences, professions, business, economics and health policy, as well as industry professionals seeking to improve their technical skills and analytical abilities. Healthcare decision analysis is a newly emerging branch of applied healthcare research that focuses on the intersection of health economics, applied health policy and insurance design, and competitive business intelligence and pricing.
Prior to joining the faculty at USC, Lawless held positions at Amgen as executive director for National Accounts and Payer Markets, executive and medical director for Managed Care Marketing, and director of Healtheconomics and Outcomes Research. Prior to joining Amgen, he served as vice president for Medical and Pharmacy Affairs for Highmark Blue Cross Blue Shield in Pittsburgh, Pennsylvania. Dr. Lawless is an author or co-author of articles appearing in Cancer, Oncology, Clinical Lymphoma, Oncology Economics, Health Affairs, the American Journal of Managed Care, the American Journal of Medical Quality, the Journal of Managed Care Pharmacy, Healtheconomics and Benefits Quarterly.
His professional experience includes internal and emergency medicine. He is board-certifed and a fellow in internal medicine, quality assurance and utilization review, as well as addiction medicine. He is also a registered pharmacist with specialty certification in nuclear medicine.
Lawless is a graduate of the University of New Mexico and completed his residency in internal medicine at the University of Pittsburgh and St. Francis Health System in Pittsburgh.
Areas of Expertise (4)
Competitive Business Intelligence and Pricing
Applied Health Policy
- Director, Business and Industry, USC Schaeffer Center
- Program Director, Healthcare Decision Analysis, USC School of Pharmacy
Selected Articles (3)
Gary M. Oderda et al.
Rheumatoid arthritis (RA) management requires monitoring of disease activity to determine course of treatment. Global assessments are used in clinical practice to determine RA disease activity. Monitoring disease activity via biomarkers may also help providers optimize biologic and nonbiologic drug use while decreasing overall drug spend by delaying use of expensive biologic therapies. By testing multiple biologic domains at the same time, a multibiomarker disease activity test may have utility in RA patient management, through improved intra- and inter-rater reliability. This report provides a comprehensive review of studies of objective measures, single biomarkers and multibiomarker disease activity tests as disease activity measures to decrease uncertainty in treatment decisions, and of biomarkers’ potential impact on economic and clinical outcomes of treatment choices.
Louise J. Short et al.
African‐American women have increased breast cancer mortality compared with white women. Diagnostic and treatment gaps may contribute to this disparity.
Cancer is seen today more often as a manageable chronic disease, resulting in changing workplace characteristics of the patient with cancer. A growing number of employees continue to work while being treated for cancer or return to work shortly after their cancer treatment is completed. To respond to these changes and the potential impact on the working patient's attitude, employers need updated, factual information related to this patient population. This type of information will support future benefit considerations by employers on employee contributions and future employee health and productivity. In 2005, Amgen launched a 3-year initiative to better understand cancer as a chronic disease, as well as the impact on the working patient with cancer and on the employer. The data from this initiative described in this article provide insights into cancer as a chronic and manageable disease in the workforce, and the broader implications to payers and employers.